BOSTON and LONDON — October 3, 2025 — Leads & Copy — Akari Therapeutics, Plc (Nasdaq: AKTX) announced that its abstract has been accepted for oral presentation at the 40th Annual SITC Meeting, scheduled for November 5-9, 2025, in National Harbor, MD.
The presentation, titled “A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity,” will be delivered by Satyajit Mitra Ph.D., Executive Director, Head of Oncology at Akari Therapeutics.
The session (No. 302), focusing on the next generation of ADCs for immune modulation beyond cytotoxic chemotherapy, is slated for Sunday, November 9, 2025, at 11:05 AM ET at the Gaylord National Resort and Convention Center – Ballroom Level – Potomac Ballroom.
Additionally, a poster presentation will take place on Friday, November 7, 2025, at the Prince George ABC Exhibit Halls of the Gaylord National Resort and Convention Center. For more information on the SITC Annual Meeting, visit sitcancer.org.
Akari Therapeutics is an oncology biotechnology company focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs). The company’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor, designed to disrupt RNA splicing within cancer cells and induce cancer cell death while activating immune cells.
Jenene Thomas
JTC Team, LLC
908-824-0775
AKTX@jtcir.com
Source: Akari Therapeutics
